期刊文献+

大肠杆菌表达的新一代重组人内皮抑素复性条件的优化

Optimization of recombinant human endostatin refolding
下载PDF
导出
摘要 目的优化新一代重组人内皮抑素(rhED)的复性方案并检测其抗血管生成活性。方法用6 mol/L盐酸胍溶解rhED包涵体后,用稀释法与透析法相结合的方法进行复性,优化最适复性条件。复性结束后用阳离子交换层析纯化。并用rhED特异性单抗和鸡胚绒毛尿囊膜实验检测复性后蛋白的活性。结果通过优化复性条件,rhED的复性率可达到46%。复性、纯化后的rhED能与rhED特异性单抗反应,并在鸡胚绒毛尿囊膜实验中显示出抑制血管生长的活性。结论提高rhED复性率的复性条件可极大地促进新一代rhED的临床前及临床研究。 Objective To optimize the conditions for enhancing the refolding of a novel recombinant human(rh) endostatin and test the biological activities of refolded endostatin.Methods The partial purified inclusion bodies of rh-endostatin were dissolved with 6 mol/L guanidine-HCl followed by combination of dilution and dialysis of the dissolved endostatin.The refolded endostatin was then purified by cation-exchange chromatography.The biological activities of purified rh-endostatin were assessed by endostatin-specific monoclonal antibody and chick embryo chorioallantoic membrane assay.Results A 46% refolding yield was achieved after optimizing the refolding conditions.The purified endostatin reacted with specific anti-endostatin monoclonal antibody and showed significant inhibition of angiogenesis in chick embryo chorioallantoic membrane assay.Conclusion The method of highest refolding yield of human endostatin was developed.This optimized method significantly promotes the application of this novel human endostatin to preclinical and clinical studies.
出处 《基础医学与临床》 CSCD 北大核心 2010年第5期492-495,共4页 Basic and Clinical Medicine
基金 国家"重大新药创制"科技重大专项(2009ZX09102-250) 江苏省高技术研究计划(BG20070605)
关键词 重组人内皮抑素 复性 纯化 鸡胚绒毛尿囊膜实验 recombinant human endostatin refolding purification chick embryo chorioallantoic membrane assay
  • 相关文献

参考文献11

  • 1O' Reilly MS, Boehm T, Shing Y, et al. Endostatin : An endogenous inhibitor of angiogenesis and tumor growth [ J ]. Cell, 1997, 88(2): 277-285.
  • 2Lee TY, Robert M, Sjin TT,et al. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy[ J]. Clin Cancer Res, 2008, 14(5) : 1487 - 1493.
  • 3Boehem T, Folkman J, Browder T, et al. Antiangiogentic therapy of experimental cancer does not induce acquired drug resistance[ J]. Nature, 1997, 390:404 -407.
  • 4Chura-Chambi RM, Genora LA, Affonso R, et al. Refolding of endostatin from inclusion bodies using high hydrostatic pressure [ J ]. Anal Biochem, 2008, 379 ( 1 ) : 32 - 39.
  • 5赵立希,孙晶晶,蒋永平.基因工程技术在生物制药领域的应用和发展[J].基础医学与临床,2009,29(9):996-998. 被引量:5
  • 6孙玉蓓,胡冰,王勇,何义富.重组人血管内皮抑素联合化疗治疗晚期大肠癌的临床观察[J].临床肿瘤学杂志,2009,14(9):837-840. 被引量:13
  • 7Robert M, Sjin TT, Satchi-Faninaro R, et al. A 27-aminoacid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity [ J ]. Cancer Res, 2005, 65 (9) : 3656 - 3663.
  • 8Hurrell J. Monoclonal hybridoma antibodies: techniques and applications [ M ]. Elorid : CRC Press, 1982:49 - 51.
  • 9Jiang YP, Pannell R, Liu JN, et al. Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes [ J ]. Blood, 1996, 87 ( 7 ) : 2775 - 2781.
  • 10Chiou GCY. Ophthalmic toxicology (target organ toxicology series) [ M ]. 2nd ed, Philadephia : Taylor & Francis, 1999 : 189 - 191.

二级参考文献38

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部